An experimental weight-loss drug with no UK marketing authorisation is being offered through online sellers, prompting renewed warnings that products labelled retatrutide may contain unknown or dangerous substances.
An investigation by Sky News on 7 November 2026 found sellers promoting the substance through social media and offering bulk supplies. Separately, the Medicines and Healthcare products Regulatory Agency (MHRA) has documented large seizures of counterfeit weight-loss injections in Britain. The regulator says retatrutide must not be sold for human use outside legitimate clinical trials.
What is retatrutide?
Retatrutide is an investigational once-weekly injectable medicine being developed by pharmaceutical company Eli Lilly. It acts on three hormone receptors involved in appetite and metabolism: GLP-1, GIP and glucagon. This is why it is sometimes described as a “triple agonist”. It is different from authorised weight-loss medicines such as semaglutide and tirzepatide.
According to Eli Lilly’s information, updated in October 2026, retatrutide is being studied in Phase 3 trials for obesity and conditions including type 2 diabetes, sleep apnoea and knee osteoarthritis. It has not been approved for public use by the UK regulator or any other medicines regulator. Products sold as retatrutide on the open market are not Lilly’s regulated trial supply.
What Sky News found
Sky News reporter Barnaby Papadopulos reported that online sellers were offering unlicensed products, including purported bulk supplies from China. The broadcaster interviewed a Yorkshire woman who said she had been hospitalised after a severe allergic reaction following an injection bought through a Facebook seller.
That experience is a warning about the potential consequences of buying injectables from unregulated suppliers. However, without independent analysis of the product, it is not possible to establish what was in the injection or whether retatrutide itself caused her reaction.
Online listings may use abbreviations, fitness-related language or descriptions such as “research use only”. Such labels do not establish a medicine’s identity, manufacturing quality or lawful status for human use. We are not identifying or linking to sellers.
Watch the Sky News investigation: Barnaby Papadopulos reports on unlicensed retatrutide sold online in the UK. The video opens on the broadcaster’s website.
What the MHRA has confirmed
The MHRA said that on 14 October 2026 it and West Midlands Police seized more than 12,000 counterfeit retatrutide and tirzepatide pens from an industrial unit in Birmingham, together with packaging intended for approximately 30,000 further products. The agency estimated the value of the seized fake medicines at around £2 million.
In its 15 October announcement, the MHRA warned that the products had not been assessed for safety, quality or effectiveness and their contents could not be guaranteed. The total seizure figure covers both retatrutide and tirzepatide-labelled pens; it is not a count for retatrutide alone.
The regulator also reported an earlier operation in May 2026 that recovered about 12,000 doses of unlicensed weight-loss medicines. North Wales Police investigated suspected illegal sales in Wrexham and Flintshire in February, reporting three arrests on suspicion of fraud by false representation. These enforcement actions show that the issue extends beyond individual social-media adverts.
What clinical trials show, and what they do not
There is credible evidence of substantial weight reduction among participants receiving carefully manufactured retatrutide in supervised studies. Eli Lilly reported average weight loss of 28.3% after 80 weeks in a higher-dose group of its TRIUMPH-1 obesity trial, with results published in the New England Journal of Medicine in September 2026.
In the separately published TRIUMPH-2 Phase 3 trial, involving 1,152 adults with obesity or overweight and type 2 diabetes, participants assigned the highest dose lost an average of 18.8% of their starting body weight over 80 weeks in the primary treatment-regimen analysis, compared with 5.1% in the placebo group.
Those figures are results from particular clinical trials and populations, not a prediction of what any individual will experience. Importantly, trial participants received studied formulations with defined dosing and medical monitoring. The results cannot be used to validate products advertised on social media, and a successful trial does not itself grant marketing authorisation.
What are the reported risks?
The TRIUMPH-2 study reported more nausea and diarrhoea among retatrutide participants than among those taking a placebo. It also identified higher rates of low blood pressure and altered skin sensations in some treatment groups. Some participants stopped treatment because of adverse events. Researchers continue to assess the medicine’s overall benefits and risks.
Illicit products create additional, separate hazards. The MHRA warns that they may contain the wrong drug, an incorrect strength or harmful contaminants, and may have been made, stored or transported without appropriate controls. In its July 2026 warning, the agency explicitly stated that retatrutide has not been authorised for use in the UK and that selling it as a medicine is illegal.
What should people do?
- Do not buy products claiming to contain retatrutide through social media, messaging groups, beauty salons or unregulated websites.
- If you are considering prescription weight-loss treatment, obtain an assessment from an appropriately qualified healthcare professional and use a registered pharmacy. You can check pharmacy registration with the General Pharmaceutical Council in Great Britain.
- If you have used a suspected counterfeit product, speak to a healthcare professional and retain the packaging where safe to do so. Report suspected adverse reactions or fake medicines via the MHRA Yellow Card scheme.
- If someone develops breathing difficulty, swelling of the throat or another sign of a severe allergic reaction, seek emergency help immediately by calling 999.
The MHRA’s public guidance on GLP-1 medicines stresses that approved prescription treatments and unregulated injections are not interchangeable. Retatrutide remains a research medicine, not a licensed UK weight-loss treatment.
Sources
- Sky News: investigation and video, 7 November 2026
- MHRA: counterfeit weight-loss pens seized, 15 October 2026
- MHRA: advice on fake weight-loss medicines, 24 July 2026
- Eli Lilly: retatrutide research and regulatory status, updated October 2026
- New England Journal of Medicine: TRIUMPH-1 Phase 3 trial, 2026
- The Lancet: TRIUMPH-2 Phase 3 trial, 2026
- North Wales Police: February 2026 investigation
